Democratic Republic of the Congo & Regeneron Pharmaceuticals

Democratic Republic of the Congo: The Democratic Republic of the Congo is the epicenter of the Ebola outbreak, facing significant challenges in containment due to conflict, aid cuts, and logistical issues. The outbreak has led to numerous deaths and widespread concern within the country and internationally.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing an ongoing outbreak of the Bundibugyo strain of Ebola, leading to the World Health Organization's recommendations for experimental treatments and vaccines.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals developed maftivimab, an experimental treatment prioritized by the World Health Organization for the Bundibugyo strain of Ebola, with supplies already in the Democratic Republic of the Congo.

Democratic Republic of the Congo: The Democratic Republic of the Congo>>> is the epicenter of the current Ebola outbreak, with hundreds of suspected cases and deaths, facing significant challenges in containment due to conflict, weak health infrastructure, and public mistrust.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.